← All trials
NCT07067866
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2025
- Primary completion
- Dec 31, 2027
- Completion date
- Oct 1, 2028
- First posted
- Jul 16, 2025
- Last posted
- Jul 16, 2025
- Enrollment
- 82
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hospital Nossa Senhora da ConceicaoLead sponsor
- Hospital Nossa Senhora da ConceicaoOfficial
- Hospital Nossa Senhora da ConceicaoSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.